Archive for the 'return on investment' Category

Generic Biologics: How to Compete

Posted by on 26th February , 2008

Guest content from John Avellanet, managing director and principal of Cerulean Associates:

Follow-on biologics are a foregone conclusion in the US. Too much money is at stake. The more difficult discussion starts with how to prepare your company to compete.
Science Succumbs to Dollars
The financial pull on reimbursement organizations and the constituent push [...]

Posted in General Biotechnology, Guest Content, customer focus, drug interactions, exclusivity, generic biologics, healthcare providers, marketplace leadership, patient population, regulatory approval, return on investment, sales and marketing | No Comments »